CHGA was considered as a biomarker for neuroendocrine neoplasms [17,18] and was approved, with microarrays and tissue arrays, as a potential biomarker for early cancer diagnosis of gastric cancer [19] and prostate cancer [20]. The gene discussed is CHGA; the disease is prostate carcinoma.